Roche Holding AG
RHO5
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
E: investor.relations@roche.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,744.30 | 169.60 | -2.14% |
| CAC 40 | 7,126.02 | 263.00 | 3.83% |
| DAX 40 | 20,562.73 | 891.85 | 4.53% |
| Dow JONES (US) | 39,577.49 | 1,030.96 | -2.54% |
| FTSE 100 | 7,913.25 | 233.77 | 3.04% |
| HKSE | 20,681.78 | 417.29 | 2.06% |
| NASDAQ | 16,421.05 | 703.92 | -4.11% |
| Nikkei 225 | 32,756.78 | 1,852.22 | -5.35% |
| NZX 50 Index | 12,036.27 | 165.16 | -1.35% |
| S&P 500 | 5,276.03 | 180.87 | -3.31% |
| S&P/ASX 200 | 7,539.10 | 170.50 | -2.21% |
| SSE Composite Index | 3,223.64 | 36.83 | 1.16% |